This 10-week double blind, placebo-controlled clinical trial will test the efficacy and safety of lumateperone in 100 older adults with treatment resistant depression (TRD) across two sites. Lumateperone is a multi- modal antipsychotic with preferential 5-HT2A blockade. It has received FDA-approval in November 2025for adjunctive treatment of Major Depressive Disorder in adults.
The purpose of this study is to test if TSND-201 is safe and effective in treating symptoms of PTSD. Approximately 300 adults, at least 18 years of age, with PTSD will participate in this research study.
